Gastrointestinal-sparing anti-inflammatory drugs: The development of nitric oxide-releasing NSAIDs
- 1 November 1997
- journal article
- research article
- Published by Wiley in Drug Development Research
- Vol. 42 (3-4) , 144-149
- https://doi.org/10.1002/(sici)1098-2299(199711/12)42:3/4<144::aid-ddr5>3.0.co;2-q
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- NO‐naproxen vs. naproxen: ulcerogenic, analgesic and anti‐inflammatory effectsAlimentary Pharmacology & Therapeutics, 1997
- Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative.Journal of Clinical Investigation, 1995
- new insights into prostaglandins and mucosal defenceAlimentary Pharmacology & Therapeutics, 1995
- Effects of very low doses of aspirin (ASA) on gastric, duodenal & rectal prostaglandins(PGs) & mucosal injuryGastroenterology, 1995
- Markedly reduced intestinal toxicity of a diclofenac derivativeLife Sciences, 1994
- Nitric oxide‐releasing non‐steroidal anti‐inflammatory drugs: A novel approach for reducing gastrointestinal toxicityJournal of Gastroenterology and Hepatology, 1994
- Adaptation in the Pharmaceutical Industry, with Particular Reference to Gastrointestinal Drugs and DiseasesScandinavian Journal of Gastroenterology, 1992
- Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic eventsThe Lancet, 1991
- Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomachLife Sciences, 1989
- GASTROSCOPIC OBSERVATION OF THE EFFECT OF ASPIRIN AND CERTAIN OTHER SUBSTANCES ON THE STOMACHThe Lancet, 1938